MedTrace Logo

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-12-09

Study results available
· View outcomes & findings →

Summary

The aim of this study is to assess the impact of the timing of intrauterine insemination (IUI) in relation to the natural surge of luteinizing hormone (LH), as detected by home ovulation predictor kits, on pregnancy rates per treatment cycle. The study will take place at the offices of Midwest Fertility Specialists and include patients who have been independently recommended by their primary physician to undergo ovulation induction with clomiphene citrate (CC) or letrozole and IUI as therapy for infertility.

Conditions

Interventions

PROCEDURE

Intrauterine Insemination

Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.

DRUG

Clomiphene

Patient is to take clomiphene citrate during cycle days 3-7.

DRUG

Letrozole

Patient is to take letrozole during cycle days 3-7.

Sponsors & Collaborators

  • Midwest Fertility Specialists

    lead INDUSTRY

Principal Investigators

  • Matthew Will, MD · Midwest Fertility Specialists

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02294773 on ClinicalTrials.gov